Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid (Q37704392)

22 August 2017

1 reference

title

Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid (English)

1 reference

22 August 2017

1 reference

Susan M Schima

1

1 reference

22 August 2017

Stephanie R Maciejewski

2

1 reference

22 August 2017

Daniel E Hilleman

3

1 reference

22 August 2017

Mark A Williams

4

1 reference

22 August 2017

Syed M Mohiuddin

5

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

1 reference

22 August 2017

11

1 reference

22 August 2017

5

1 reference

22 August 2017

731-738

1 reference

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Fibrates after the FIELD study: Some answers, more questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Do triglycerides provide meaningful information about heart disease risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Comparative effects of lipid-lowering therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

High density lipoprotein cholesterol and incidence of coronary heart disease--the Israeli Ischemic Heart Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Statin-fibrate combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903575639

10.1517/14656560903575639

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference